Evidence map›Paper›PMID 36039063›Full record

ArticleOncology letters2022

Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer

Yoonjung Jang, Won Seok Lee, Sei Sai, Jeong Yub Kim, Jong-Ki Kim, Eun Ho Kim

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Yoonjung JangDepartment of Biochemistry, School of Medicine, Daegu Catholic University, Daegu, North Gyeongsang 42471, Republic of Korea.
Won Seok LeeDepartment of Biochemistry, School of Medicine, Daegu Catholic University, Daegu, North Gyeongsang 42471, Republic of Korea.
Sei SaiDepartment of Basic Medical Sciences for Radiation Damage, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Jeong Yub KimDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.
Jong-Ki KimDepartment of Biomedical Engineering and Radiology, School of Medicine, Daegu Catholic University, Daegu, North Gyeongsang 42471, Republic of Korea.
Eun Ho KimDepartment of Biochemistry, School of Medicine, Daegu Catholic University, Daegu, North Gyeongsang 42471, Republic of Korea.
Catholic University of Daegu · KRNational Institutes for Quantum and Radiological Science and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer is a common malignancy worldwide, with a poor prognosis and a high recurrence rate despite the available treatment methodologies. Tumor-treating fields (TTFields) have shown good preclinical and clinical results for improving the prognosis of patients with glioblastoma and malignant pleural mesothelioma. However, there is minimal evidence for the effect of TTFields on other cancer types. Thus, the present study aimed to investigate the therapeutic efficacy of TTFields in an

Indexed as

apoptosisliver cancersorafenibtumor-treating fields

Identifiers

PMID36039063
PMCPMC9404698
OpenAlexW4290999312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.